List of Utibron drug patents

Utibron is owned by Novartis.

Utibron contains Glycopyrrolate; Indacaterol Maleate.

Utibron has a total of 3 drug patents out of which 0 drug patents have expired.

Utibron was authorised for market use on 29 October, 2015.

Utibron is available in powder;inhalation dosage forms.

Utibron can be used as long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).

The generics of Utibron are possible to be released after 20 October, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730 NOVARTIS Inhaler device
Oct, 2028

(5 years from now)

US8182838 NOVARTIS Dry powder composition comprising co-jet milled particles for pulmonary inhalation
Oct, 2028

(5 years from now)

Drugs and Companies using GLYCOPYRROLATE; INDACATEROL MALEATE ingredient

Market Authorisation Date: 29 October, 2015

Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER;INHALATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in